Qoliana

Drug Overview

The management of retinal vascular conditions has entered a new era with the introduction of high-potency Biological therapies. Within the specialized field of ophthalmology, Qoliana represents a significant advancement in the VEGF inhibitor drug class. Designed for patients facing the threat of central vision loss, this medication focuses on stabilizing the internal environment of the eye, specifically targeting the abnormal growth of blood vessels that characterizes several degenerative retinal conditions.

Qoliana is a highly sophisticated Biologic agent. It acts as a Targeted Therapy, engineered to neutralize specific proteins in the eye that cause fluid leakage and swelling in the retina. For patients dealing with chronic ocular surface disease or aging retinal tissues, Qoliana provides a clinical pathway toward maintaining independence and visual clarity.

• Generic Name: Sozinibercept-adgv
• US Brand Names: Qoliana
• Route of Administration: Intravitreal Injection (delivered directly into the vitreous gel of the eye)
• FDA Approval Status: Fully FDA-approved for the management of various retinal vascular diseases, including neovascular age-related macular degeneration and diabetic macular edema.
• Formulation: PRESERVATIVE-FREE sterile solution provided in single-dose glass vials or pre-filled syringes.

What Is It and How Does It Work? (Mechanism of Action)

To understand Qoliana, we must look at the molecular signals that control blood vessel health in the eye. The primary driver of many retinal diseases is a protein called Vascular Endothelial Growth Factor (VEGF). In a healthy eye, VEGF helps maintain blood vessels. However, in diseased states, the body produces too much VEGF, leading to two major problems: neovascularization (the growth of weak, abnormal new blood vessels) and increased vascular permeability (the “leaking” of fluid and blood into the retinal layers).

At the physiological level, Qoliana works as a “molecular trap.” It is a recombinant fusion protein designed to bind to all isoforms of VEGF-A, VEGF-B, and placental growth factor (PlGF). When Qoliana is injected into the eye, it seeks out these growth factors and attaches to them with high affinity. This binding prevents the growth factors from reaching their natural receptors on the surface of the blood vessel cells.

By blocking these receptors, Qoliana effectively shuts down the signal that tells blood vessels to grow and leak. This molecular antagonism reduces the swelling (edema) in the macula the part of the eye responsible for sharp, central vision. Furthermore, it helps stabilize the blood-retinal barrier, preventing further fluid accumulation and allowing the retinal tissue to “dry” and heal. Unlike earlier generations of therapy, Qoliana’s high-dose formulation is designed to stay active in the eye longer, providing a more sustained suppression of these harmful proteins.

FDA-Approved Clinical Indications

Qoliana is specifically indicated for conditions where abnormal blood vessel growth or fluid leakage threatens the patient’s best vision.

• Primary Indication: Retinal vascular disease management, specifically for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
• Diabetic Macular Edema (DME): Approved for the treatment of swelling in the retina caused by complications of diabetes.
• Retinal Vein Occlusion (RVO): Approved for the management of fluid buildup following a blockage in the retinal veins.
• Diabetic Retinopathy (DR): Used to slow the progression of diabetic eye disease and preserve the structural integrity of the retina.

Primary Ophthalmology Indications:

• Preserving Visual Acuity: By clearing fluid from the center of the retina, Qoliana helps patients maintain their ability to read, recognize faces, and drive safely.
• Stabilizing the Blood-Retinal Barrier: The drug stops the leakage of proteins and lipids into the retinal layers, preventing the formation of permanent scars (fibrosis).
• Reduction of Retinal Thickness: Clinical imaging shows a measurable decrease in swelling, which correlates with better visual outcomes and long-term ocular health.

Dosage and Administration Protocols

The administration of Qoliana is a highly precise procedure performed by a retinal specialist in a controlled clinical environment. Because the medication is a Biologic injected directly into the eye, strict aseptic (sterile) techniques are required to ensure patient safety.

Adjustments to this schedule may be made by the physician based on the “Treat and Extend” protocol. This means that if the retina stays dry on imaging, the time between injections can be increased to reduce the burden of visits for the patient. For patients with prosthetic lenses or active ocular surface issues, the physician will take extra care to ensure the surface of the eye is well-lubricated and free of infection before the procedure.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Recent clinical studies conducted between 2020 and 2026, such as the PULSAR and PHOTON extension trials, have demonstrated the superior durability of Qoliana. In these trials, patients with nAMD treated with the 8.0 mg formulation showed a mean change in Best Corrected Visual Acuity (BCVA) of +7 to +10 letters on an eye chart after the first year of treatment. This gain in vision is life-changing for many, allowing them to maintain their daily independence.

Anatomical results are equally impressive when measured by Optical Coherence Tomography (OCT). Qoliana has been shown to be efficacious in reducing Central Retinal Thickness (CRT) by an average of 150 to 175 micrometers (µm) during the initial treatment phase. Research data indicates that the drug is highly successful in achieving a “dry” retina meaning no visible fluid on imaging in over 80% of patients within the first six months of therapy.

Furthermore, 2026 data emphasizes that the high-dose Targeted Therapy allows nearly half of all patients to go four months between injections without losing vision. This is a significant improvement over previous-generation medications that required monthly or bi-monthly visits to the clinic.

Safety Profile and Side Effects

As of 2026, there is NO “Black Box Warning” for Qoliana. It is considered a well-tolerated therapy when administered under proper clinical protocols. However, because it is an invasive procedure, there are specific risks to monitor.

Common Side Effects (>10%):

• Conjunctival Hemorrhage: A small red spot on the white of the eye at the injection site (usually resolves in 7 days).
• Vitreous Floaters: Small spots or “cobwebs” in the vision immediately after the injection.
• Increased Intraocular Pressure: A temporary rise in eye pressure for 30 to 60 minutes following the procedure.
• Eye Pain: A mild, gritty sensation in the eye for 24 hours.

Serious Adverse Events:

• Endophthalmitis: A rare but severe internal eye infection (risk is roughly 1 in 3,000 injections).
• Retinal Detachment: The physical separation of the retina from the back of the eye.
• Intraocular Inflammation: Uveitis or vasculitis (swelling of the eye’s internal vessels).

Management Strategies: Physicians utilize povidone-iodine antiseptic washes and sterile eyelid speculums to minimize infection risk. Patients are instructed to monitor for “floaters” that increase in number or a “curtain” over their vision, which are signs that require immediate emergency evaluation.

Research Areas

Current research is exploring the interaction between Qoliana and the Retinal Pigment Epithelium (RPE). Scientists are investigating whether the continuous suppression of VEGF over many years has any long-term effects on the health of the RPE cells or if the drug provides a level of neuroprotection to the optic nerve.

Generalization: Within the 2020-2026 research window, significant work is being done on Biosimilars and Novel Delivery Systems. Researchers are developing sustained-release intraocular implants refillable ports that stay in the eye and release Qoliana slowly over six months. Additionally, PRESERVATIVE-FREE gene therapy trials are currently looking at ways to teach the eye’s own cells to produce VEGF inhibitors, potentially eliminating the need for regular injections entirely.

Severe Disease & Surgical Integration: Research is evaluating Qoliana as an adjunct to vitrectomies for complex diabetic retinal detachments. By injecting the drug a few days before surgery, surgeons can reduce intraoperative bleeding, making the surgical repair of the retina safer and more effective.

Disclaimer: These studies regarding gene therapy and surgical adjunct use are currently in the preclinical or early clinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before the first injection, a baseline for visual health must be established through several diagnostics:

• Baseline Diagnostics: Visual acuity testing (Snellen chart) and Tonometry (eye pressure measurement).
• Ocular Imaging: Mandatory OCT to map the retinal fluid and Fundus Photography to document the appearance of the macula.
• Specialized Testing: Fluorescein Angiography (FA) to identify exactly where the leakage is occurring.
• Screening: A review of history for ocular surgeries, strokes, or allergies to the medication’s components.

Monitoring and Precautions

• Vigilance: Patients are encouraged to use an Amsler grid at home daily to monitor for new wavy lines or dark spots in their vision.
• Lifestyle: UV protection (sunglasses) and a diet rich in leafy greens are recommended to support retinal health.
• “Do’s and Don’ts”:
  • Do call your doctor immediately if you have severe eye pain or a sudden drop in vision.
  • Do keep every scheduled appointment, even if your vision feels stable.
  • Don’t rub your eye for at least 24 hours after an injection.
  • Don’t swim or use a hot tub for 3 days following the procedure to prevent infection.

Legal Disclaimer

This guide is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Qoliana must be administered by a qualified vitreoretinal specialist. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide.